Arg217
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.7
Powered by Cell Signaling Technology
Home > Di-methylation Site Page: > Arg217  -  hnRNP H1 (human)

Site Information
yDrPGAGrGyNsIGr   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 9480315

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 )
Disease tissue studied:
colorectal cancer ( 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 ) , colorectal carcinoma ( 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 )
Relevant cell line - cell type - tissue:
HCT116 (intestinal) ( 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 ) , HeLa S3 (cervical) ( 1 ) , Jurkat (T lymphocyte) ( 2 )

References 

1

Bremang M, et al. (2013) Mass spectrometry-based identification and characterisation of lysine and arginine methylation in the human proteome. Mol Biosyst 9, 2231-47
23748837   Curated Info

2

Uhlmann T, et al. (2012) A method for large-scale identification of protein arginine methylation. Mol Cell Proteomics 11, 1489-99
22865923   Curated Info

3

Possemato A (2010) CST Curation Set: 8858; Year: 2010; Biosample/Treatment: cell line, HCT 116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: mR
Curated Info

4

Possemato A (2010) CST Curation Set: 8855; Year: 2010; Biosample/Treatment: cell line, HCT 116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: mR
Curated Info

5

Possemato A (2010) CST Curation Set: 8852; Year: 2010; Biosample/Treatment: cell line, HCT 116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: mR
Curated Info

6

Possemato A (2010) CST Curation Set: 8859; Year: 2010; Biosample/Treatment: cell line, HCT 116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: mR
Curated Info

7

Possemato A (2010) CST Curation Set: 8854; Year: 2010; Biosample/Treatment: cell line, HCT 116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: mR
Curated Info

8

Possemato A (2010) CST Curation Set: 8857; Year: 2010; Biosample/Treatment: cell line, HCT 116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: mR
Curated Info

9

Possemato A (2010) CST Curation Set: 8853; Year: 2010; Biosample/Treatment: cell line, HCT 116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: mR
Curated Info

10

Possemato A (2010) CST Curation Set: 8856; Year: 2010; Biosample/Treatment: cell line, HCT 116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: mR
Curated Info

11

Zhou J (2008) CST Curation Set: 5145; Year: 2008; Biosample/Treatment: cell line, HCT116/Adox; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: mR
Curated Info

12

Zhou J (2008) CST Curation Set: 5146; Year: 2008; Biosample/Treatment: cell line, HCT116/Adox; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: mR
Curated Info